Thermo Fisher Scientific Asia Pacific — Consolidated revenues increased by 4.7% to $2.01B in Q3 2025 compared to the prior quarter. Year-over-year, this metric grew by 4.7%, from $1.92B to $2.01B. This is a positive signal — higher values indicate stronger performance for this metric.
An increase indicates successful market expansion, strong regional demand, or effective sales execution in the Asia-Pacific territory, while a decrease may signal regional economic headwinds, increased local competition, or supply chain disruptions.
This metric represents the total gross revenue generated by the company's operations within the Asia-Pacific geographic...
Peers in the life sciences and diagnostics sector typically report regional revenue to demonstrate geographic diversification and exposure to high-growth markets like China and India.
tmo_segment_asia_pacific_consolidated_revenues| Q2 '21 | Q1 '22 | Q2 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q3 '24 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|
| Value | $1.75B | $2.06B | $2.04B | $1.97B | $1.97B | $1.97B | $1.97B | $1.92B | $2.01B |
| QoQ Change | — | +18.0% | -1.1% | -3.6% | +0.0% | +0.0% | +0.0% | -2.3% | +4.7% |
| YoY Change | — | — | +16.8% | -4.6% | -3.6% | — | — | -2.3% | +4.7% |
We use cookies for analytics. See our Privacy and Cookie Policy.